The research behind this platform

Question: Which withdrawal symptoms are valid and how long do they last?

Found: Valid withdrawal symptoms include craving, irritability, restlessness, difficulty concentrating, depressed mood, insomnia, and increased appetite. Most symptoms peak in the first week and resolve within 2–4 weeks; craving and increased appetite can persist longer.

Limitations: Derived largely from clinical trial data; individual variation is substantial.

Evidence strength: Strong · DOI: 10.1080/14622200701188919

Question: Does nicotine replacement therapy (NRT) help people quit smoking?

Found: NRT in any form (gum, patch, lozenge, inhaler, spray) increases the rate of quitting by roughly 50% to 70% compared with placebo or no medication, regardless of the setting.

Limitations: Absolute quit rates remain modest; most participants do not succeed even with NRT.

Evidence strength: Strong · DOI: 10.1002/14651858.CD000146.pub4

Question: How effective are varenicline and cytisine for smoking cessation?

Found: Varenicline roughly doubles to triples the odds of quitting compared with placebo in clinical trials. Cytisine also increases quit rates compared with placebo.

Limitations: Trials mostly exclude people with unstable psychiatric conditions; post-marketing safety discussions continue.

Evidence strength: Strong · DOI: 10.1002/14651858.CD006103.pub4

Question: What are the mortality risks of continued smoking, and what are the benefits of quitting at different ages?

Found: Smokers lose about a decade of life on average. Quitting before age 40 avoids roughly 90% of the excess risk; quitting at 50–59 avoids a substantial share, with benefits at every age.

Limitations: Observational design; smoking behavior self-reported at baseline.

Evidence strength: Strong · DOI: 10.1056/NEJMsa1211128

Question: How do the main cessation medications compare with each other?

Found: Combination NRT and varenicline rank among the most effective options, followed by single-form NRT and bupropion, all clearly better than placebo.

Limitations: Network meta-analysis assumptions; trial populations may differ from typical smokers.

Evidence strength: Strong · DOI: 10.1002/14651858.CD009329.pub2

Question: Do antidepressants, particularly bupropion, help people quit smoking?

Found: Bupropion roughly doubles quit rates compared with placebo and is effective regardless of depression history. Nortriptyline also helps; other antidepressants show less evidence.

Limitations: Bupropion is less effective than varenicline and combination NRT in indirect comparisons; contraindications apply.

Evidence strength: Strong · DOI: 10.1002/14651858.CD000031.pub3

Question: Is quitting abruptly more effective than cutting down gradually before quitting?

Found: People who quit abruptly were more likely to achieve abstinence than those who reduced gradually first. Both approaches produced some successful quitters.

Limitations: Trials varied in how reduction was defined and supported; participants were treatment-seekers.

Evidence strength: Moderate · DOI: 10.1002/14651858.CD010332.pub2

Question: Are nicotine e-cigarettes more effective than conventional NRT for quitting smoking?

Found: One-year abstinence was 18.0% in the e-cigarette group versus 9.9% in the NRT group. E-cigarette users reported less severe urges and more throat/mouth irritation.

Limitations: Products and setting (UK stop-smoking service with behavioral support) may limit generalizability; long-term safety remains open.

Evidence strength: Moderate · DOI: 10.1056/NEJMoa1808779

Question: What does the current evidence say about how to help people quit smoking?

Found: Smoking cessation benefits health at any age; combination approaches (medication plus counseling) are most effective; quitlines, NRT, varenicline and bupropion all have strong evidence.

Limitations: US-focused; guidelines evolve as new evidence appears.

Evidence strength: Strong

Question: Do nicotine e-cigarettes help people quit smoking, and how safe are they?

Found: Moderate-certainty evidence that nicotine e-cigarettes increase quit rates compared with NRT, and compared with behavioral support alone. Serious adverse events were rare in trials.

Limitations: Long-term health effects remain uncertain; product landscape changes quickly.

Evidence strength: Moderate · DOI: 10.1002/14651858.CD010216

Question: What does NICE recommend for smoking cessation support in clinical practice?

Found: Offer combination NRT, varenicline or bupropion alongside behavioral support; e-cigarettes can be considered as a stop-smoking aid within local regulations; support should be person-centered and repeated.

Limitations: UK healthcare context; regulatory status of medications varies internationally.

Evidence strength: Strong

Question: What are the global health impacts of tobacco, and what works for cessation?

Found: Tobacco kills more than 8 million people annually; within 20 minutes of quitting heart rate drops, and longer-term risks decline substantially over years. WHO recommends population-level cessation support.

Limitations: Aggregated global figures; country-level variation.

Evidence strength: Strong